Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Blum

Showing results (221-230 of 336) with videos related to

Pageof 34
Sort By:
Psychology Research and Behavior Management|December 24, 2021
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management"Kenneth Blum, Bruce Steinberg, Marjorie C Gondre-Lewis, et al.
Acta Scientific Neurology|August 29, 2025
Theorizing The Role of Gama Type Endorphins in Schizophrenia and Alcoholism: Promoting Genetic Testing and Attempts at Inducing "Dopamine Homeostasis"Kenneth Blum, Kai Uwe Lewandowski, Alireza Sharafshah, et al.
Medical Hypotheses|October 31, 2006
Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS)Kenneth Blum, Thomas J H Chen, Brian Meshkin, et al.
Plos One|April 27, 2017
Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220ZMarcelo Febo, Kenneth Blum, Rajendra D Badgaiyan, et al.
Journal of Integrative Neuroscience|July 4, 2025
Exercise Leads to Brain Glucose Metabolism Activation, Increased Dopamine D1 Receptor Levels and is Negatively Correlated with Social BehaviorMichael Bobick, Colin Hanna, John Tyler, et al.
INNOSC Theranostics & Pharmacological Sciences|August 9, 2024
A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependenceMark S Gold, Kenneth Blum, Abdalla Bowirrat, et al.
Biomedicines|April 23, 2022
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?Marjorie C Gondré-Lewis, Igor Elman, Tanya Alim, et al.
Biomedical Journal of Scientific & Technical Research|October 30, 2018
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid CrisisKenneth Blum, Edward J Modestino, Jennifer Neary, et al.
Acta Scientific Neurology|August 9, 2024
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight LossEdward J Modestino, Abdalla Bowirrat, Kai-Uwe Lewandrowski, et al.
Open Journal of Immunology|November 21, 2022
Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of "Dopamine Homeostasis"Kenneth Blum, Catherine A Dennen, Eric R Braverman, et al.
Pageof 34

Showing results (221-230 of 336) with videos related to

Sort By:
Pageof 34
Psychology Research and Behavior Management|December 24, 2021
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management"Kenneth Blum, Bruce Steinberg, Marjorie C Gondre-Lewis, et al.
Acta Scientific Neurology|August 29, 2025
Theorizing The Role of Gama Type Endorphins in Schizophrenia and Alcoholism: Promoting Genetic Testing and Attempts at Inducing "Dopamine Homeostasis"Kenneth Blum, Kai Uwe Lewandowski, Alireza Sharafshah, et al.
Medical Hypotheses|October 31, 2006
Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS)Kenneth Blum, Thomas J H Chen, Brian Meshkin, et al.
Plos One|April 27, 2017
Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220ZMarcelo Febo, Kenneth Blum, Rajendra D Badgaiyan, et al.
Journal of Integrative Neuroscience|July 4, 2025
Exercise Leads to Brain Glucose Metabolism Activation, Increased Dopamine D1 Receptor Levels and is Negatively Correlated with Social BehaviorMichael Bobick, Colin Hanna, John Tyler, et al.
INNOSC Theranostics & Pharmacological Sciences|August 9, 2024
A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependenceMark S Gold, Kenneth Blum, Abdalla Bowirrat, et al.
Biomedicines|April 23, 2022
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?Marjorie C Gondré-Lewis, Igor Elman, Tanya Alim, et al.
Biomedical Journal of Scientific & Technical Research|October 30, 2018
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid CrisisKenneth Blum, Edward J Modestino, Jennifer Neary, et al.
Acta Scientific Neurology|August 9, 2024
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight LossEdward J Modestino, Abdalla Bowirrat, Kai-Uwe Lewandrowski, et al.
Open Journal of Immunology|November 21, 2022
Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of "Dopamine Homeostasis"Kenneth Blum, Catherine A Dennen, Eric R Braverman, et al.
Pageof 34